Cerebral Neurodegeneration and Cognitive Impairment in Patients on Maintenance Hemodialysis: the Role of Neuroglia and Associated Factors (Review)

Chronic kidney disease (CKD), which often requires maintenance hemodialysis (MHD), represents a model of accelerated aging. Therefore, understanding the mechanisms underlying cerebral neurodegeneration (CND) and cognitive impairment (CI) in patients undergoing MHD is of particular importance. Brain damage in patients with end-stage CKD is considered a multicomponent process associated with the impact of cerebrovascular, neurodegenerative, and numerous dysmetabolic factors. Special attention is given to CND mechanisms mediated by the activation of microglia and astrocytes. The high prevalence of CI in the general population and especially among patients with end-stage CKD undergoing MHD determines the need to clarify CND risk factors and biomarkers. Furthermore, it is essential to explore therapeutic targets, as well as modifiable modern strategies and technologies aimed at slowing the CND progression.

This review synthesizes data on the role of neuroglia and associated factors in the development of CND and CI in MHD patients. It presents the mechanisms and factors affecting neuroglia and involved in the pathogenesis of CND and CI. Particular focus is placed on chronic systemic inflammation, the effects of uremic toxins, and the activation of the cerebral renin-angiotensin-aldosterone system. The article studies such chronic systemic inflammatory factors associated with neuroglia as protein S100B, IL-1β, IL-6, TNF-α, and fibrinogen. Experimental and clinical data investigating the impact of uremic toxins (indoxyl sulfate, p-cresol sulfate, and imidazole propionate) on microglia and astrocytes, as well as the activation of the cerebral renin-angiotensin-aldosterone system, are analyzed. Potential further clinical research fields aimed at slowing the CND and CI progression in this patient population are highlighted.

1. Battaglia S., Avenanti A., Vécsei L., Tanaka M. Neurodegeneration in cognitive impairment and mood disorders for experimental, clinical and translational neuropsychiatry. Biomedicines 2024; 12(3): 574, https://doi.org/10.3390/biomedicines12030574.
2. Klinicheskie rekomendatsii "Kognitivnye rasstroystva u lits pozhilogo i starcheskogo vozrasta" [Clinical guidelines "Cognitive impairment in elderly and senile individuals"]. 2024. URL: https://cr.minzdrav.gov.ru/preview-cr/617_5.
3. Bai W., Chen P., Cai H., Zhang Q., Su Z., Cheung T., Jackson T., Sha S., Xiang Y.T. Worldwide prevalence of mild cognitive impairment among community dwellers aged 50 years and older: a meta-analysis and systematic review of epidemiology studies. Age Ageing 2022; 51(8): afac173, https://doi.org/10.1093/ageing/afac173.
4. Sakurai T., Sugimoto T., Akatsu H., Doi T., Fujiwara Y., Hirakawa A., Kinoshita F., Kuzuya M., Lee S., Matsumoto N., Matsuo K., Michikawa M., Nakamura A., Ogawa S., Otsuka R., Sato K., Shimada H., Suzuki H., Suzuki H., Takechi H., Takeda S., Uchida K., Umegaki H., Wakayama S., Arai H.; J-MINT study group. Japan-multimodal intervention trial for the prevention of dementia: a randomized controlled trial. Alzheimers Dement 2024; 20(6): 3918–3930, https://doi.org/10.1002/alz.13838.
5. Bushell D., Jones C., Moro C. The effectiveness of educational interventions in the community that aim to improve informal carers knowledge of dementia anatomy, physiology, progression, and impact on behavior: a systematic review. Front Dement 2023; 2: 1156863, https://doi.org/10.3389/frdem.2023.1156863.
6. Starchina Y.A. Cognitive impairment without dementia: a current view of the problem. Nevrologiya, neiropsikhiatriya, psikhosomatika 2017; 9(2): 71–76, https://doi.org/10.14412/2074-2711-2017-2-71-76.
7. Tkacheva O.N., Kotovskaya Yu.V., Bobkova I.N., Shutov A.M., Villevalde S.V., Efremova E.V., Runikhina N.K., Eruslanova K.A., Arutyunov G.P., Batyushin M.M., Frolova E.V. Chronic kidney disease in older adults. Consensus statement of Russian Association of Gerontologists and Geriatricians, Scientific Society of Nephrologists of Russia and Eurasian Association of Therapists. Russian Journal of Geriatric Medicine 2024; 1: 6–20, https://doi.org/10.37586/2686-8636-1-2024-6-20.
8. International Society of Nephrology (ISN). ISN Global Kidney Health Atlas. 2023. URL: https://www.theisn.org/initiatives/global-kidney-health-atlas/.
9. Klinicheskie rekomendatsii "Khronicheskaya bolezn' pochek (KBP)" [Clinical guidelines "Chronic kidney disease (CKD)"]. 2024. URL: https://cr.minzdrav.gov.ru/preview-cr/469_3.
10. Andrusev A.M., Peregudova N.G., Shinkarev M.B., Tomilina N.A. Kidney replacement therapy for end stage kidney disease in Russian Federation, 2016–2020 Russian National Kidney Replacement Therapy. Registry report of Russian Public Organization of Nephrologists "Russian Dialysis Society". Nephrology and Dialysis 2022; 24(4): 555–565, https://doi.org/10.28996/2618-9801-2022-4-555-565.
11. Arnold R., Issar T., Krishnan A.V., Pussell B.A. Neurological complications in chronic kidney disease. JRSM Cardiovasc Dis 2016; 5: 2048004016677687, https://doi.org/10.1177/2048004016677687.
12. Khrulev A.Е., Tolbuzova D.D., Plokhenko E.A., Egorova P.A., Sorokoumova S.N., Suvorova O.V., Yankevich D.S. Cognitive status and risk factors for cognitive impairment in dialysis patients. General Reanimatology 2020; 16(4): 21–31, https://doi.org/10.15360/1813-9779-2020-4-21-31.
13. Smakotina S.A., Bohanov Y.A., Fomina N.V. Indicators of neurodynamics and attention in patients with the end stage kidney disease. Influence of hemodialysis procedures. Nephrology 2020; 24(4): 67–72, https://doi.org/10.36485/1561-6274-2020-24-4-67-72.
14. Karakizlis H., Bohl K., Ziemek J., Dodel R., Hoyer J. Assessment of cognitive impairment and related risk factors in hemodialysis patients. J Nephrol 2022; 35(3): 931–942, https://doi.org/10.1007/s40620-021-01170-3.
15. Park B.S., Lee H.W., Lee Y.J., Park S., Kim Y.W., Kim S.E., Kim I.H., Park J.H., Park K.M. Serum S100B represents a biomarker for cognitive impairment in patients with end-stage renal disease. Clin Neurol Neurosurg 2020; 195: 105902, https://doi.org/10.1016/j.clineuro.2020.105902.
16. Natale G., Calabrese V., Marino G., Campanelli F., Urciuolo F., de Iure A., Ghiglieri V., Calabresi P., Bossola M., Picconi B. Effects of uremic toxins on hippocampal synaptic transmission: implication for neurodegeneration in chronic kidney disease. Cell Death Discov 2021; 7(1): 295, https://doi.org/10.1038/s41420-021-00685-9.
17. Hamed S.A. Neurologic conditions and disorders of uremic syndrome of chronic kidney disease: presentations, causes, and treatment strategies. Expert Rev Clin Pharmacol 2019; 12(1): 61–90, https://doi.org/10.1080/17512433.2019.1555468.
18. Michna M., Kovarova L., Valerianova A., Malikova H., Weichet J., Malik J. Review of the structural and functional brain changes associated with chronic kidney disease. Physiol Res 2020; 69(6): 1013–1028, https://doi.org/10.33549/physiolres.934420.
19. Pei X., Bakerally N.B., Wang Z., Bo Y., Ma Y., Yong Z., Zhu S., Gao F., Bei Z., Zhao W. Kidney function and cognitive impairment: a systematic review and meta-analysis. Ren Fail 2025; 47(1): 2463565, https://doi.org/10.1080/0886022X.2025.2463565.
20. Khrulev A.E., Studyanikova S.F., Langran S.V., Sadyrin R.V., Grigorieva V.N. Cognitive impairment in patients undergoing program hemodialysis. Nevrologicheskii vestnik 2019; 51(2): 36–40.
21. Olczyk P., Kusztal M., Gołębiowski T., Letachowicz K., Krajewska M. Cognitive impairment in end stage renal disease patients undergoing hemodialysis: markers and risk factors. Int J Environ Res Public Health 2022; 19(4): 2389, https://doi.org/10.3390/ijerph19042389.
22. Yusupov F., Yuldashev A., Yusupov A., Ormonova G., Abdykadyrov M. Neurological disorders in chronic kidney disease. The Scientific Heritage 2022; 84(2): 51–61.
23. Adesso S., Magnus T., Cuzzocrea S., Campolo M., Rissiek B., Paciello O., Autore G., Pinto A., Marzocco S. Indoxyl sulfate affects glial function increasing oxidative stress and neuroinflammation in chronic kidney disease: interaction between astrocytes and microglia. Front Pharmacol 2017; 8: 370, https://doi.org/10.3389/fphar.2017.00370.
24. Hachatryan A.A., Erofeeva L.M., Kutvickaya S.A. The role of neuroglia in the functioning of the nervous system. Uspekhi sovremennogo estestvoznaniya 2014; 6: 66–70.
25. Huang J., Li C., Shang H. Astrocytes in neurodegeneration: inspiration from genetics. Front Neurosci 2022; 16: 882316, https://doi.org/10.3389/fnins.2022.882316.
26. Hickman S., Izzy S., Sen P., Morsett L., El Khoury J. Microglia in neurodegeneration. Nat Neurosci 2018; 21(10): 1359–1369, https://doi.org/10.1038/s41593-018-0242-x.
27. Augusto-Oliveira M., Arrifano G.P., Lopes-Araújo A., Santos-Sacramento L., Takeda P.Y., Anthony D.C., Malva J.O., Crespo-Lopez M.E. What do microglia really do in healthy adult brain? Cells 2019; 8(10): 1293, https://doi.org/10.3390/cells8101293.
28. Gotoh M., Miyamoto Y., Ikeshima-Kataoka H. Astrocytic neuroimmunological roles interacting with microglial cells in neurodegenerative diseases. Int J Mol Sci 2023; 24(2): 1599, https://doi.org/10.3390/ijms24021599.
29. Mendiola A.S., Yan Z., Dixit K., Johnson J.R., Bouhaddou M., Meyer-Franke A., Shin M.G., Yong Y., Agrawal A., MacDonald E., Muthukumar G., Pearce C., Arun N., Cabriga B., Meza-Acevedo R., Alzamora M.D.P.S., Zamvil S.S., Pico A.R., Ryu J.K., Krogan N.J., Akassoglou K. Defining blood-induced microglia functions in neurodegeneration through multiomic profiling. Nat Immunol 2023; 24(7): 1173–1187, https://doi.org/10.1038/s41590-023-01522-0.
30. Mohamed W., Kumar J., Alghamdi B.S., Soliman A.H., Toshihide Y. Neurodegeneration and inflammation crosstalk: therapeutic targets and perspectives. IBRO Neurosci Rep 2022; 14: 95–110, https://doi.org/10.1016/j.ibneur.2022.12.003.
31. Verkhratsky A., Ho M.S., Zorec R., Parpura V. The concept of neuroglia. Adv Exp Med Biol 2019; 1175: 1–13, https://doi.org/10.1007/978-981-13-9913-8_1.
32. Bon E.I., Maksimovich N.E., Malykhina A.V. Neuroglia and its role in the pathogenesis of ischemic brain damage. immunohistochemical markers of neuroglia. Vestnik Smolenskoj gosudarstvennoj medicinskoj akademii 2021; 20(3): 18–24, https://doi.org/10.37903/vsgma.2021.3.3.
33. Al-Onaizi M., Al-Khalifah A., Qasem D., ElAli A. Role of microglia in modulating adult neurogenesis in health and neurodegeneration. Int J Mol Sci 2020; 21(18): 6875, https://doi.org/10.3390/ijms21186875.
34. Reyes-Haro D., López-Juárez A., Rodríguez-Contreras A. Editorial: Physiology and pathology of neuroglia. Front Cell Neurosci 2023; 17: 1246885, https://doi.org/10.3389/fncel.2023.1246885.
35. Patlay N.I., Sotnikov E.B., Tuchina O.P. The role of microglial cytokines in the modulation of neurogenesis in the adult brain. Mezhdunarodnyj zhurnal prikladnyh i fundamental'nyh issledovanij 2020; 5: 15–23, https://doi.org/10.17513/mjpfi.13062.
36. Malinovskaya N.A., Frolova O.V., Shishelova K.O., Panina Yu.A. Current methods for the isolation and cultivation of microglia (review). Sovremennye tehnologii v medicine 2021; 13(6): 89, https://doi.org/10.17691/stm2021.13.6.10.
37. Li D., Wu M. Pattern recognition receptors in health and diseases. Signal Transduct Target Ther 2021; 6(1): 291, https://doi.org/10.1038/s41392-021-00687-0.
38. Amarante-Mendes G.P., Adjemian S., Branco L.M., Zanetti L.C., Weinlich R., Bortoluci K.R. Pattern recognition receptors and the host cell death molecular machinery. Front Immunol 2018; 9: 2379, https://doi.org/10.3389/fimmu.2018.02379.
39. Jin M.M., Wang F., Qi D., Liu W.W., Gu C., Mao C.J., Yang Y.P., Zhao Z., Hu L.F., Liu C.F. A critical role of autophagy in regulating microglia polarization in neurodegeneration. Front Aging Neurosci 2018; 10: 378, https://doi.org/10.3389/fnagi.2018.00378.
40. Mata-Martínez E., Díaz-Muñoz M., Vázquez-Cuevas F.G. Glial cells and brain diseases: inflammasomes as relevant pathological entities. Front Cell Neurosci 2022; 16: 929529, https://doi.org/10.3389/fncel.2022.929529.
41. Lee J.W., Chun W., Lee H.J., Kim S.M., Min J.H., Kim D.Y., Kim M.O., Ryu H.W., Lee S.U. The role of microglia in the development of neurodegenerative diseases. Biomedicines 2021; 9(10): 1449, https://doi.org/10.3390/biomedicines9101449.
42. Stoklund Dittlau K., Freude K. Astrocytes: the stars in neurodegeneration? Biomolecules 2024; 14(3): 289, https://doi.org/10.3390/biom14030289.
43. Tienda-Vazquez M.A., Arredondo P., Mejía-Delgadillo X., Rodríguez-González J.A., Soto-Cajiga J.A., Sabath E., Lozano O., Almanza-Arjona Y.C. Biological testing unification for hemodialysis membranes evaluation: a step towards standardization. Biomater Adv 2025; 169: 214165, https://doi.org/10.1016/j.bioadv.2024.214165.
44. Strokov G.A., Gurevich K.Ya., Ilyin A.P., Denisov A. Yu., Zemchenkov A.Yu., Andrusov A.M., Shutov E.V., Kotenko O.N., Zlokazov V.B. Treatment of patients with chronic kidney disease stage 5 (CKD 5) by hemodialysis and hemodiafiltration. clinical guidelines. Nephrology 2017; 21(3): 92–111, https://doi.org/10.24884/1561-6274-2017-3-92-111.
45. Chen Y.A., Ou S.M., Lin C.C. Influence of dialysis membranes on clinical outcomes: from history to innovation. Membranes (Basel) 2022; 12(2): 152, https://doi.org/10.3390/membranes12020152.
46. Strokov A.G., Poz I.L. High dialysis membranes permeability: pluses and minuses. Russian Journal of Transplantology and Artificial Organs 2018; 20(4): 100–106, https://doi.org/10.15825/1995-1191-2018-4-100-106.
47. Abdelrasoul A., Westphalen H., Saadati S., Shoker A. Hemodialysis biocompatibility mathematical models to predict the inflammatory biomarkers released in dialysis patients based on hemodialysis membrane characteristics and clinical practices. Sci Rep 2021; 11(1): 23080, https://doi.org/10.1038/s41598-021-01660-1.
48. Pénzes K., Hurják B., Katona É., Becs G., Balla J., Muszbek L. Terminal phase components of the clotting cascade in patients with end-stage renal disease undergoing hemodiafiltration or hemodialysis treatment. Int J Mol Sci 2020; 21(22): 8426, https://doi.org/10.3390/ijms21228426.
49. Belova I.V., Khrulev A.E., Tochilina A.G., Khruleva N.S., Lobanova N.A., Zhirnov V.A., Molodtsova S.B., Lobanov V.N., Solovieva I.V. Colon microbiocenosis and its correction in patients receiving programmed hemodialysis. Sovremennye tehnologii v medicine 2021; 12(5): 62–68, https://doi.org/10.17691/stm2020.12.5.07.
50. Rapa S.F., Di Iorio B.R., Campiglia P., Heidland A., Marzocco S. Inflammation and oxidative stress in chronic kidney disease-potential therapeutic role of minerals, vitamins and plant-derived metabolites. Int J Mol Sci 2019; 21(1): 263, https://doi.org/10.3390/ijms21010263.
51. Supriyadi R., Rakhmawati Kurniaatmaja E., Huang I., Sukesi L., Makmun A. The effect of superoxide dismutase supplementation on TNF-α and TGF-β levels in patients undergoing hemodialysis. Eur Rev Med Pharmacol Sci 2023; 27(3): 893–898, https://doi.org/10.26355/eurrev_202302_31182.
52. Kunz M., Ceresér K.M., Goi P.D., Fries G.R., Teixeira A.L., Fernandes B.S., Belmonte-de-Abreu P.S., Kauer-Sant'Anna M., Kapczinski F., Gama C.S. Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Braz J Psychiatry 2011; 33(3): 268–274, https://doi.org/10.1590/s1516-44462011000300010.
53. Aitbaev K.A., Murkamilov I.T., Fomin V.V., Murkamilova J.A., Rayimzhanov Z.R., Yusupov F.A., Aidarov Z.A. Inflammation in chronic kidney disease: sources, consequences and anti-inflammatory therapy. Clinical Medicine 2018; 96(4): 314–320, https://doi.org/10.18821/0023-2149-2018-96-4-314-320.
54. Al-Hakeim H.K., Twaij B.A.A., Al-Naqeeb T.H., Moustafa S.R., Maes M. Neuronal damage and inflammatory biomarkers are associated with the affective and chronic fatigue-like symptoms due to end-stage renal disease. J Affect Disord 2024; 347: 220–229, https://doi.org/10.1016/j.jad.2023.11.078.
55. Angelopoulou E., Paudel Y.N., Piperi C. Emerging role of S100B protein implication in Parkinson's disease pathogenesis. Cell Mol Life Sci 2021; 78(4): 1445–1453, https://doi.org/10.1007/s00018-020-03673-x.
56. Hernández-Ortega K., Canul-Euan A.A., Solis-Paredes J.M., Borboa-Olivares H., Reyes-Muñoz E., Estrada-Gutierrez G., Camacho-Arroyo I. S100B actions on glial and neuronal cells in the developing brain: an overview. Front Neurosci 2024; 18: 1425525, https://doi.org/10.3389/fnins.2024.1425525.
57. Michetti F., Clementi M.E., Di Liddo R., Valeriani F., Ria F., Rende M., Di Sante G., Romano Spica V. The S100B protein: a multifaceted pathogenic factor more than a biomarker. Int J Mol Sci 2023; 24(11): 9605, https://doi.org/10.3390/ijms24119605.
58. Markelova E.V., Zenina A.A., Kadyrov R.V. Neuropeptides as markers of brain damage. Sovremennye problemy nauki i obrazovaniya 2018; 5: 206.
59. Fomina N.V., Egorova M.V., Smakotina S.A., Kvitkova L.V. S100B protein, neuron specific enolase and cognitive dysfunction in patients with chronic kidney disease. Nephrology 2019; 23(4): 73–79, https://doi.org/10.24884/1561-6274-2019-23-4-73-79.
60. Bossola M., Picca A., Marzetti E., Pepe G., Antocicco M., Di Stasio E. Post-dialysis fatigue and serum S100B protein in patients on chronic hemodialysis. A pilot study. Ther Apher Dial 2023; 27(3): 471–479, https://doi.org/10.1111/1744-9987.13944.
61. Barros C., Barateiro A., Neto A., Soromenho B., Basto A.P., Mateus J.M., Xapelli S., Sebastião A.M., Brites D., Graça L., Fernandes A. S100B inhibition protects from chronic experimental autoimmune encephalomyelitis. Brain Commun 2022; 4(3): fcac076, https://doi.org/10.1093/braincomms/fcac076.
62. Stanciu G.D., Ababei D.C., Bild V., Bild W., Paduraru L., Gutu M.M., Tamba B.I. Renal contributions in the pathophysiology and neuropathological substrates shared by chronic kidney disease and Alzheimer's disease. Brain Sci 2020; 10(8): 563, https://doi.org/10.3390/brainsci10080563.
63. Gryka-Marton M., Grabowska A.D., Szukiewicz D. Breaking the barrier: the role of proinflammatory cytokines in BBB dysfunction. Int J Mol Sci 2025; 26(8): 3532, https://doi.org/10.3390/ijms26083532.
64. Perna A.F., Russo L., D'Esposito V., Formisano P., Bruzzese D., Vigorito C., Coppola A., Lombari P., Russo D., Ingrosso D. Lanthionine, a novel uremic toxin, in the vascular calcification of chronic kidney disease: the role of proinflammatory cytokines. Int J Mol Sci 2021; 22(13): 6875, https://doi.org/10.3390/ijms22136875.
65. Zhu B., Jin L.N., Shen J.Q., Liu J.F., Jiang R.Y., Yang L., Zhang J., Luo A.L., Miao L.Y., Yang C. Differential expression of serum biomarkers in hemodialysis patients with mild cognitive decline: a prospective single-center cohort study. Sci Rep 2018; 8(1): 12250, https://doi.org/10.1038/s41598-018-29760-5.
66. Hernandez L., Ward L.J., Arefin S., Ebert T., Laucyte-Cibulskiene A; GOING-FWD Collaborators; Heimbürger O., Barany P., Wennberg L., Stenvinkel P., Kublickiene K. Blood-brain barrier and gut barrier dysfunction in chronic kidney disease with a focus on circulating biomarkers and tight junction proteins. Sci Rep 2022; 12(1): 4414, https://doi.org/10.1038/s41598-022-08387-7.
67. Vafadar-Afshar G., Rasmi Y., Yaghmaei P., Khadem-Ansari M.H., Makhdoomi K., Rasouli J. The effects of nanocurcumin supplementation on inflammation in hemodialysis patients: a randomized controlled trial. Hemodial Int 2021; 25(2): 232–239, https://doi.org/10.1111/hdi.12911.
68. Lindblad C., Rostami E., Helmy A. Interleukin-1 receptor antagonist as therapy for traumatic brain injury. Neurotherapeutics 2023; 20(6): 1508–1528, https://doi.org/10.1007/s13311-023-01421-0.
69. Mendiola A.S., Cardona A.E. The IL-1β phenomena in neuroinflammatory diseases. J Neural Transm (Vienna) 2018; 125(5): 781–795, https://doi.org/10.1007/s00702-017-1732-9.
70. Liu X., Quan N. Microglia and CNS interleukin-1: beyond immunological concepts. Front Neurol 2018; 9: 8, https://doi.org/10.3389/fneur.2018.00008.
71. Skelly D.T., Griffin É.W., Murray C.L., Harney S., O'Boyle C., Hennessy E., Dansereau M.A., Nazmi A., Tortorelli L., Rawlins J.N., Bannerman D.M., Cunningham C. Acute transient cognitive dysfunction and acute brain injury induced by systemic inflammation occur by dissociable IL-1-dependent mechanisms. Mol Psychiatry 2019; 24(10): 1533–1548, https://doi.org/10.1038/s41380-018-0075-8.
72. Armada-Moreira A., Gomes J.I., Pina C.C., Savchak O.K., Gonçalves-Ribeiro J., Rei N., Pinto S., Morais T.P., Martins R.S., Ribeiro F.F., Sebastião A.M., Crunelli V., Vaz S.H. Going the extra (synaptic) mile: excitotoxicity as the road toward neurodegenerative diseases. Front Cell Neurosci 2020; 14: 90, https://doi.org/10.3389/fncel.2020.00090.
73. Boraschi D., Italiani P., Migliorini P., Bossù P. Cause or consequence? The role of IL-1 family cytokines and receptors in neuroinflammatory and neurodegenerative diseases. Front Immunol 2023; 14: 1128190, https://doi.org/10.3389/fimmu.2023.1128190.
74. Retinasamy T., Shaikh M.F. Interleukin 1 receptor antagonist and neurodegenerative diseases: the future treatment strategy. Neurosci Res Notes 2023; 6(1): 164, https://doi.org/10.31117/neuroscirn.v6i1.164.
75. Dember L.M., Hung A., Mehrotra R., Hsu J.Y., Raj D.S., Charytan D.M., Mc Causland F.R., Regunathan-Shenk R., Landis J.R., Kimmel P.L., Kliger A.S., Himmelfarb J., Ikizler T.A.; Hemodialysis Novel Therapies Consortium. A randomized controlled pilot trial of anakinra for hemodialysis inflammation. Kidney Int 2022; 102(5): 1178–1187, https://doi.org/10.1016/j.kint.2022.06.022.
76. Recasens M., Almolda B., Pérez-Clausell J., Campbell I.L., González B., Castellano B. Chronic exposure to IL-6 induces a desensitized phenotype of the microglia. J Neuroinflammation 2021; 18(1): 31, https://doi.org/10.1186/s12974-020-02063-1.
77. Kerkis I., da Silva Á.P., Araldi R.P. The impact of interleukin-6 (IL-6) and mesenchymal stem cell-derived IL-6 on neurological conditions. Front Immunol 2024; 15: 1400533, https://doi.org/10.3389/fimmu.2024.1400533.
78. Rose-John S., Jenkins B.J., Garbers C., Moll J.M., Scheller J. Targeting IL-6 trans-signalling: past, present and future prospects. Nat Rev Immunol 2023; 23(10): 666–681, https://doi.org/10.1038/s41577-023-00856-y.
79. Chertow G.M., Chang A.M., Felker G.M., Heise M., Velkoska E., Fellström B., Charytan D.M., Clementi R., Gibson C.M., Goodman S.G., Jardine M., Levin A., Lokhnygina Y., Mears J., Mehran R., Stenvinkel P., Wang A.Y., Wheeler D.C., Zoccali C., Ridker P.M., Mahaffey K.W., Tricoci P., Wolf M. IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial. Nat Med 2024; 30(8): 2328–2336, https://doi.org/10.1038/s41591-024-03043-1.
80. Voronina E.V., Lobanova N.V., Yakhin I.R., Romanova N.A., Seregin Yu.A. Role of tumor necrosis factor alpha in immune pathogenesis of different diseases and its significance for evolving anticytokine therapy with monoclonal antibodies. Medical Immunology 2018; 20(6): 797–806, https://doi.org/10.15789/1563-0625-2018-6-797-806.
81. Sasidharakurup H., Diwakar S. Computational modelling of TNFα related pathways regulated by neuroinflammation, oxidative stress and insulin resistance in neurodegeneration. Appl Netw Sci 2020; 5(1): 72, https://doi.org/10.1007/s41109-020-00307-w.
82. Samy A.E., Elrahman A.A.M., El Shafei M., Adel A.O., Ahmed S.I. The relation between the level of serum tumor necrosis factor-alpha and hemodialysis adequacy in diabetic and non diabetic patients on maintenance hemodialysis. Urol Nephrol Open Access J 2016; 3(2): 60–65.
83. Kantor A.B., Akassoglou K., Stavenhagen J.B. Fibrin-targeting immunotherapy for dementia. J Prev Alzheimers Dis 2023; 10(4): 647–660, https://doi.org/10.14283/jpad.2023.105.
84. Pluvinage J.V., Wyss-Coray T. Systemic factors as mediators of brain homeostasis, ageing and neurodegeneration. Nat Rev Neurosci 2020; 21(2): 93–102, https://doi.org/10.1038/s41583-019-0255-9.
85. Petersen M.A., Ryu J.K., Akassoglou K. Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics. Nat Rev Neurosci 2018; 19(5): 283–301, https://doi.org/10.1038/nrn.2018.13.
86. Wen T., Zhang Z. Cellular mechanisms of fibrin (ogen): insight from neurodegenerative diseases. Front Neurosci 2023; 17: 1197094, https://doi.org/10.3389/fnins.2023.1197094.
87. Sulimai N., Brown J., Lominadze D. The role of fibrinogen in neurodegeneration during a neuroinflammatory disease. Alzheimer's Dement 2023; 19(S17): e075879, https://doi.org/10.1002/alz.075879.
88. Fan D.Y., Sun H.L., Sun P.Y., Jian J.M., Li W.W., Shen Y.Y., Zeng F., Wang Y.J., Bu X.L. The correlations between plasma fibrinogen with amyloid-beta and tau levels in patients with Alzheimer's disease. Front Neurosci 2021; 14: 625844, https://doi.org/10.3389/fnins.2020.625844.
89. Pyun J.M., Ryoo N., Park Y.H., Kim S. Fibrinogen levels and cognitive profile differences in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 2020; 49(5): 489–496, https://doi.org/10.1159/000510420.
90. Seidel U.K., Gronewold J., Volsek M., Todica O., Kribben A., Bruck H., Hermann D.M. The prevalence, severity, and association with HbA1c and fibrinogen of cognitive impairment in chronic kidney disease. Kidney Int 2014; 85(3): 693–702, https://doi.org/10.1038/ki.2013.366.
91. Tampubolon G. Repeated systemic inflammation was associated with cognitive deficits in older Britons. Alzheimers Dement (Amst) 2015; 3: 1–6, https://doi.org/10.1016/j.dadm.2015.11.009.
92. Pedersen A., Stanne T.M., Redfors P., Viken J., Samuelsson H., Nilsson S., Jood K., Jern C. Fibrinogen concentrations predict long-term cognitive outcome in young ischemic stroke patients. Res Pract Thromb Haemost 2018; 2(2): 339–346, https://doi.org/10.1002/rth2.12078.
93. Lin Y.T., Wu P.H., Liang S.S., Mubanga M., Yang Y.H., Hsu Y.L., Kuo M.C., Hwang S.J., Kuo P.L. Protein-bound uremic toxins are associated with cognitive function among patients undergoing maintenance hemodialysis. Sci Rep 2019; 9(1): 20388, https://doi.org/10.1038/s41598-019-57004-7.
94. Liabeuf S., Pepin M., Franssen C.F.M., Viggiano D., Carriazo S., Gansevoort R.T., Gesualdo L., Hafez G., Malyszko J., Mayer C., Nitsch D., Ortiz A., Pešić V., Wiecek A., Massy Z.A.; CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target). Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle? Nephrol Dial Transplant 2021; 37(Suppl 2): ii33–ii44, https://doi.org/10.1093/ndt/gfab223.
95. Connell E., Le Gall G., Pontifex M.G., Sami S., Cryan J.F., Clarke G., Müller M., Vauzour D. Microbial-derived metabolites as a risk factor of age-related cognitive decline and dementia. Mol Neurodegener 2022; 17(1): 43, https://doi.org/10.1186/s13024-022-00548-6.
96. Falconi C.A., Junho C.V.D.C., Fogaça-Ruiz F., Vernier I.C.S., da Cunha R.S., Stinghen A.E.M., Carneiro-Ramos M.S. Uremic toxins: an alarming danger concerning the cardiovascular system. Front Physiol 2021; 12: 686249, https://doi.org/10.3389/fphys.2021.686249.
97. Xu Y., Bi W.D., Shi Y.X., Liang X.R., Wang H.Y., Lai X.L., Bian X.L., Guo Z.Y. Derivation and elimination of uremic toxins from kidney-gut axis. Front Physiol 2023; 14: 1123182, https://doi.org/10.3389/fphys.2023.1123182.
98. Swer N.M., Venkidesh B.S., Murali T.S., Mumbrekar K.D. Gut microbiota-derived metabolites and their importance in neurological disorders. Mol Biol Rep 2023; 50(2): 1663–1675, https://doi.org/10.1007/s11033-022-08038-0.
99. Sun C.Y., Li J.R., Wang Y.Y., Lin S.Y., Ou Y.C., Lin C.J., Wang J.D., Liao S.L., Chen C.J. p-Cresol sulfate caused behavior disorders and neurodegeneration in mice with unilateral nephrectomy involving oxidative stress and neuroinflammation. Int J Mol Sci 2020; 21(18): 6687, https://doi.org/10.3390/ijms21186687.
100. Bobot M. Cognitive impairment and the blood-brain barrier in chronic kidney disease: role of the uremic toxins. Nephrol Ther 2023; 19(7): 607–615, https://doi.org/10.1684/ndt.2023.51.
101. Bobot M., Thomas L., Moyon A., Fernandez S., McKay N., Balasse L., Garrigue P., Brige P., Chopinet S., Poitevin S., Cérini C., Brunet P., Dignat-George F., Burtey S., Guillet B., Hache G. Uremic toxic blood-brain barrier disruption mediated by AhR activation leads to cognitive impairment during experimental renal dysfunction. J Am Soc Nephrol 2020; 31(7): 1509–1521, https://doi.org/10.1681/ASN.2019070728.
102. Faucher Q., van der Made T.K., De Lange E., Masereeuw R. Blood-brain barrier perturbations by uremic toxins: key contributors in chronic kidney disease-induced neurological disorders? Eur J Pharm Sci 2023; 187: 106462, https://doi.org/10.1016/j.ejps.2023.106462.
103. Sankowski B., Księżarczyk K., Raćkowska E., Szlufik S., Koziorowski D., Giebułtowicz J. Higher cerebrospinal fluid to plasma ratio of p-cresol sulfate and indoxyl sulfate in patients with Parkinson's disease. Clin Chim Acta 2020; 501: 165–173, https://doi.org/10.1016/j.cca.2019.10.038.
104. Brito J.S., Borges N.A., Anjos J.S.D., Nakao L.S., Stockler-Pinto M.B., Paiva B.R., Cardoso-Weide L.C., Cardozo L.F.M.F., Mafra D. Aryl hydrocarbon receptor and uremic toxins from the gut microbiota in chronic kidney disease patients: is there a relationship between them? Biochemistry 2019; 58(15): 2054–2060, https://doi.org/10.1021/acs.biochem.8b01305.
105. Laville S.M., Massy Z.A., Kamel S., Chillon J.M., Choukroun G., Liabeuf S. Intestinal chelators, sorbants, and gut-derived uremic toxins. Toxins (Basel) 2021; 13(2): 91, https://doi.org/10.3390/toxins13020091.
106. Deltombe O., Van Biesen W., Glorieux G., Massy Z., Dhondt A., Eloot S. Exploring protein binding of uremic toxins in patients with different stages of chronic kidney disease and during hemodialysis. Toxins (Basel) 2015; 7(10): 3933–3946, https://doi.org/10.3390/toxins7103933.
107. Lin Y.T., Wu P.H., Tsai Y.C., Hsu Y.L., Wang H.Y., Kuo M.C., Kuo P.L., Hwang S.J. Indoxyl sulfate induces apoptosis through oxidative stress and mitogen-activated protein kinase signaling pathway inhibition in human astrocytes. J Clin Med 2019; 8(2): 191, https://doi.org/10.3390/jcm8020191.
108. Davoli-Ferreira M., Thomson C.A., McCoy K.D. Microbiota and microglia interactions in ASD. Front Immunol 2021; 12: 676255, https://doi.org/10.3389/fimmu.2021.676255.
109. Tevzadze G., Barbakadze T., Kvergelidze E., Zhuravliova E., Shanshiashvili L., Mikeladze D. Gut neurotoxin p-cresol induces brain-derived neurotrophic factor secretion and increases the expression of neurofilament subunits in PC-12 cells. AIMS Neurosci 2021; 9(1): 12–23, https://doi.org/10.3934/Neuroscience.2022002.
110. Lukichyov B.G., Strelko V.V., Mosikyan A.A., Trihleb V.A. The current state of the use of enterosorption in chronic kidney disease. Nefrologiya 2014; 18(6): 43–50.
111. Aytbaev K.A., Murkamilov I.T., Kaliev R.R. Chronic kidney disease: pathophysiological role of dysbiosis of intestine and renoprotective effectiveness of interventions concerning its modulation. Russian Medicine 2016; 22(3): 157–162, https://doi.org/10.18821/0869-2106-2016-22-4-157-162.
112. Abiodun O.A., Ola M.S. Role of brain renin angiotensin system in neurodegeneration: an update. Saudi J Biol Sci 2020; 27(3): 905–912, https://doi.org/10.1016/j.sjbs.2020.01.026.
113. Karlovich N.V., Mohort T.V., Volchek Y.A. Renin-angiotensin-aldosterone system: traditional function and pleiotropic effects of regulation of phosphorus-calcium metabolism. Medicinskie novosti 2021; 10: 22–26.
114. Cruz-López E.O., Uijl E., Danser A.H.J. Fifty years of research on the brain renin-angiotensin system: what have we learned? Clin Sci (Lond) 2021; 135(14): 1727–1731, https://doi.org/10.1042/CS20210579.
115. Villapol S., Janatpour Z.C., Affram K.O., Symes A.J. The renin angiotensin system as a therapeutic target in traumatic brain injury. Neurotherapeutics 2023; 20(6): 1565–1591, https://doi.org/10.1007/s13311-023-01435-8.
116. Labandeira-Garcia J.L., Rodríguez-Perez A.I., Garrido-Gil P., Rodriguez-Pallares J., Lanciego J.L., Guerra M.J. Brain renin-angiotensin system and microglial polarization: implications for aging and neurodegeneration. Front Aging Neurosci 2017; 9: 129, https://doi.org/10.3389/fnagi.2017.00129.
117. Gouveia F., Camins A., Ettcheto M., Bicker J., Falcão A., Cruz M.T., Fortuna A. Targeting brain renin-angiotensin system for the prevention and treatment of Alzheimer's disease: past, present and future. Ageing Res Rev 2022; 77: 101612, https://doi.org/10.1016/j.arr.2022.101612.
118. Singh K.D., Karnik S.S. Angiotensin receptors: structure, function, signaling and clinical applications. J Cell Signal (Los Angel) 2016; 1(2): 111, https://doi.org/10.4172/2576-1471.1000111.
119. Musina N.S., Semenova R.I., Sejdumanov M.T., Kurazov B.R. Efficiency of antihypertensive therapy in patients on hemodialysis. Vestnik Kazahskogo Nacional'nogo medicinskogo universiteta 2015; 1: 255–256.
120. Kang S.H., Kim B.Y., Son E.J., Kim G.O., Do J.Y. Association of renin-angiotensin system blockers with survival in patients on maintenance hemodialysis. J Clin Med 2023; 12(9): 3301, https://doi.org/10.3390/jcm12093301.

Khrulev A.E., Chernova O.M., Grigoryeva V.N., Shiianova N.A., Khruleva N.S., Mukhina I.V. Cerebral Neurodegeneration and Cognitive Impairment in Patients on Maintenance Hemodialysis: the Role of Neuroglia and Associated Factors (Review). Sovremennye tehnologii v medicine 2026; 18(1): 54, https://doi.org/10.17691/stm2026.18.1.05